3.95
-0.13 (-3.19%)
| Penutupan Terdahulu | 4.08 |
| Buka | 4.08 |
| Jumlah Dagangan | 908,673 |
| Purata Dagangan (3B) | 3,611,811 |
| Modal Pasaran | 669,269,824 |
| Harga / Pendapatan (P/E TTM) | 13.17 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.20 |
| Harga / Jualan (P/S) | 4.10 |
| Harga / Buku (P/B) | 6.07 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | 28.19% |
| Margin Operasi (TTM) | 44.43% |
| EPS Cair (TTM) | 0.480 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 70.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.53% |
| Nisbah Semasa (MRQ) | 1.73 |
| Aliran Tunai Operasi (OCF TTM) | -81.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.07 M |
| Pulangan Atas Aset (ROA TTM) | 15.87% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | CytomX Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.83% |
| % Dimiliki oleh Institusi | 47.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Adar1 Capital Management, Llc | 30 Sep 2025 | 4,045,414 |
| Balyasny Asset Management L.P. | 30 Sep 2025 | 3,913,081 |
| Kynam Capital Management, Lp | 30 Sep 2025 | 3,646,503 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (HC Wainwright & Co., 153.17%) | Beli |
| Median | 6.00 (51.90%) | |
| Rendah | 6.00 (Cantor Fitzgerald, 51.90%) | Beli |
| 6.00 (Barclays, 51.90%) | Beli | |
| Purata | 7.33 (85.57%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 3.26 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Nov 2025 | 10.00 (153.16%) | Beli | 4.10 |
| Barclays | 21 Oct 2025 | 6.00 (51.90%) | Beli | 3.62 |
| 17 Sep 2025 | 3.50 (-11.39%) | Beli | 1.93 | |
| Cantor Fitzgerald | 22 Sep 2025 | 6.00 (51.90%) | Beli | 2.06 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | CytomX Therapeutics to Present at Upcoming December Investor Conferences |
| 13 Nov 2025 | Pengumuman | CytomX Therapeutics to Present at the Jefferies London Healthcare Conference |
| 06 Nov 2025 | Pengumuman | CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update |
| 04 Nov 2025 | Pengumuman | CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting |
| 30 Oct 2025 | Pengumuman | CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 20 Oct 2025 | Pengumuman | CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |